Tunlametinib is under clinical development by Binjiang Pharma and currently in Phase II for Neurofibromatoses Type I (Von Recklinghausen’s Disease). According to GlobalData, Phase II drugs for Neurofibromatoses Type I (Von Recklinghausen’s Disease) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tunlametinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tunlametinib overview

Tunlametinib (HL-085) is under development for the treatment of advanced solid tumors with BRAF V600 mutation, metastatic colorectal cancer, neurofibromatoses type I mutant plexiform neurofibroma, non-small cell lung cancer and NRAS mutant advanced melanoma. It is formulated as the capsule and administered through oral route. The drug candidate acts by targeting dual specificity mitogen-activated protein kinase kinase 1 (MEK1).

Binjiang Pharma overview

Binjiang Pharma is a biopharmaceutical company. It offers drug discovery, process development and customized services. The company, together with its partners develops targeted small molecule drugs, which has competitive advantages over the existing therapies. Binjiang Pharma is headquartered in Tianjin, China.

For a complete picture of Tunlametinib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.